In a recent study, Jiao et al. aimed to evaluate a threshold for current clinical PLND-validated nomograms to predict nonregional pelvic and extrapelvic lymph node metastasis in 57 high-risk prostate cancer patients studied with 68Ga-PSMA PET/CT. This evidence concerns the gene FOLH1 and metastatic malignant neoplasm in the lymph nodes.